Study guide
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki
Key Takeaways Explain This Topic AI
The Nuremberg Code (1947) established that the voluntary informed consent of the human subject is absolutely essential and that research must yield fruitful societal results unprocurable by other methods.
The 1962 Kefauver-Harris Amendments to the U.S. FD&C Act, triggered by the global Thalidomide tragedy, mandated proof of drug efficacy, safety, and mandatory subject informed consent prior to clinical trial enrollment.
The World Medical Association's Declaration of Helsinki (1964, continuously revised) established the fundamental principle that the health, well-being, and rights of the individual subject must always take precedence over the interests of science and society.
The Tuskegee Syphilis Study and Willowbrook Hepatitis experiments exposed egregious exploitation of vulnerable populations, directly prompting the National Research Act of 1974 and the Belmont Report (1979).
Modern Good Clinical Practice (ICH GCP E6) directly operationalizes the ethical architecture established by Nuremberg, Helsinki, and Belmont into enforceable international regulatory standards.
Last updated: August 2026
Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki
Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is the Declaration of Helsinki (2024 revision) and ICH E6(R3) Principle 1 , which anchors GCP in it.
Quick Reference: Contemporary human research protection did not arise spontaneously; it was forged in response to catastrophic ethical abuses and exploitation. The Nuremberg Code (1947) established voluntary informed consent as inviolable. The Declaration of Helsinki (WMA 1964) affirmed that a subject's welfare must always supersede the interests of science or society. The Belmont Report (1979) , catalyzed by the public exposure of the Tuskegee Syphilis Study, codified the foundational ethical triad: Respect for Persons, Beneficence, and Justice. Together with the 1962 Kefauver-Harris Amendments , these frameworks form the bedrock of modern Good Clinical Practice (ICH GCP).
On the ACRP-CP (ACRP Certified Professional) exam, questions concerning historical ethics assess not merely your recall of dates and names, but your understanding of why specific regulatory safeguards exist today. Understanding the historical context equips clinical research professionals to identify subtle ethical hazards, safeguard vulnerable participants, and maintain uncompromising compliance with international GCP standards.
1. Historical Tragedies and Catalysts for Ethical Reform
Modern clinical research regulations are essentially a codification of lessons learned from historical atrocities where human beings were treated as disposable experimental material or denied standard medical care in the pursuit of scientific data. ┌───────────────────────────────────────────────────────────────────────────┐
- │ CHRONOLOGY OF ETHICAL CRISIS AND REGULATORY REACTION │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1932–1972: Tuskegee Syphilis Study (US PHS withholds penicillin) │
- │ 1946–1947: Doctors' Trial at Nuremberg ──────► Nuremberg Code (1947) │
- │ 1956–1970: Willowbrook Hepatitis Study (Infecting disabled children) │
- │ Late 1950s: Thalidomide Catastrophe ─────────► Kefauver-Harris (1962) │
- │ 1964: WMA Adopts ──────────────────────► Declaration of Helsinki │
- │ 1972–1974: Tuskegee Exposed ────────────────► National Research Act (1974)│
- │ 1979: Commission Publishes ────────────► Belmont Report (1979) │
- │ 1996: Harmonization ───────────────────► ICH GCP Guidelines (E6) │
- └───────────────────────────────────────────────────────────────────────────┘
- A. Nazi Medical War Crimes & The Doctors' Trial (1946–1947)
During World War II, German physicians conducted horrific, non-consensual medical experiments on concentration camp prisoners in Dachau, Auschwitz, Buchenwald, and Ravensbrück. These experiments included:
High-Altitude and Hypothermia Experiments: Subjecting prisoners to extreme atmospheric decompression and freezing water tanks to calculate survival thresholds for Luftwaffe pilots.
Infectious Disease Inoculations: Deliberately infecting prisoners with malaria, typhus, and epidemic jaundice to test experimental therapies.
Chemical Warfare and Trauma Experiments: Inflicting mustard gas burns, phosphorus bomb injuries, and traumatic amputations/bone grafting.
Mass Sterilization: Evaluating surgical, radiation, and chemical methods for mass genetic annihilation.
At the conclusion of the war, the International Military Tribunal conducted the Doctors' Trial (United States v. Karl Brandt et al.) at Nuremberg. Twenty-three defendants were tried for war crimes and crimes against humanity. In August 1947, the presiding American judges issued their verdict, which included a section titled "Permissible Medical Experiments" —a 10-point standard that became globally known as the Nuremberg Code .
B. The Tuskegee Syphilis Study (1932–1972)
The Tuskegee Study of Untreated Syphilis in the Negro Male is widely recognized as the most egregious domestic research abuse in United States history:
Sponsor & Population: Conducted by the U.S. Public Health Service (USPHS) in collaboration with the Tuskegee Institute in Macon County, Alabama. The study enrolled 600 impoverished African American sharecroppers (399 men with latent syphilis and 201 uninfected control subjects).
The Ethical Violation: The men were never told they had syphilis. Instead, they were told they had "bad blood" (a local colloquialism encompassing anemia, fatigue, and various ailments) and were offered free medical exams, hot meals, and a $50 burial insurance benefit to secure their participation.
Deliberate Denial of Treatment: When penicillin became recognized as the safe, validated, and curative standard of care for syphilis in the late 1940s, the researchers deliberately withheld the antibiotic from the participants. Furthermore, researchers actively prevented the men from receiving penicillin from local health clinics and military draft boards, ensuring that the men remained untreated so researchers could track the natural history of the disease through autopsy upon their deaths.
Exposure & Regulatory Aftermath: In 1972, Peter Buxtun, a USPHS social worker and epidemiologist who had repeatedly raised ethical objections internally, leaked the details to the press (Associated Press journalist Jean Heller). The resulting public outrage led to Senate hearings chaired by Senator Edward Kennedy, the immediate termination of the study, the passage of the National Research Act of 1974 , and the formation of the National Commission that authored the Belmont Report .
C. The Willowbrook Hepatitis Experiments (1956–1970s)
At the Willowbrook State School in Staten Island, New York—an overcrowded, unsanitary state institution for children with severe intellectual and developmental disabilities—Dr. Saul Krugman and associates conducted research on viral hepatitis:
The Study Design: Newly admitted children aged 5 to 10 were deliberately inoculated with live hepatitis virus (strains isolated from feces) to study the development of immunity, differentiate Hepatitis A from Hepatitis B, and test the prophylactic efficacy of gamma globulin.
Ethical Exploitation & Coercion: The investigators defended the study by claiming that hepatitis was already endemic at Willowbrook and that the children would contract it anyway in the cleaner research ward. However, institutional admissions were closed due to overcrowding, and desperate parents were told that the only available beds for their children were in the experimental hepatitis research unit. This created severe institutional coercion, rendering parental consent ethically invalid.
D. The Thalidomide Tragedy & The 1962 Kefauver-Harris Amendments
In the late 1950s and early 1960s, Thalidomide (Kevadon/Contergan) was aggressively marketed in Europe, Canada, and other nations as a non-barbiturate sedative and anti-emetic for morning sickness in pregnant women:
The Teratogenic Disaster: Thalidomide caused severe phocomelia (a catastrophic congenital malformation resulting in flipper-like or absent limbs), cranial nerve palsy, and internal organ failure in over 10,000 infants worldwide.
The FDA Defense: In the United States, FDA medical reviewer Dr. Frances Kelsey refused to approve the New Drug Application (NDA) for Richardson-Merrell, citing a lack of clinical toxicology and peripheral neuropathy safety data, despite tremendous commercial and political pressure.
The Regulatory Transformation: The tragedy revealed that the manufacturer had already distributed millions of sample tablets to over 1,200 U.S. physicians for "investigational clinical evaluation" without patient knowledge or consent. In response, Congress unanimously passed the 1962 Kefauver-Harris Drug Amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act. This landmark legislation established:
Mandatory Proof of Efficacy: Drug sponsors must demonstrate substantial evidence of effectiveness through adequate and well-controlled clinical trials prior to marketing approval (not merely safety).
Informed Consent Requirement: Clinical trial investigators must obtain the explicit informed consent of participants before administering investigational drugs.
Adverse Reaction Reporting: Mandatory expedited reporting of adverse drug reactions to the FDA.
Strict Manufacturing Standards: Formalization of Good Manufacturing Practices (GMP) and mandatory FDA factory inspections.
2. Comparative Matrix of Historical Abuses and Resulting Reforms
Event / Tragedy Timeframe Subject Population Core Ethical Abuses Resulting Regulatory Safeguard
Nazi Medical War Crimes 1939–1945 Concentration camp prisoners Involuntary experimentation, extreme torture, permanent mutilation, deliberate lethality Nuremberg Code (1947): Established primacy of voluntary informed consent, risk/benefit ratio, right to terminate.
Thalidomide Tragedy 1957–1962 Pregnant women & fetuses globally Teratogenicity; unapproved "investigational seeding" trials without patient consent Kefauver-Harris Amendments (1962): Mandated proof of efficacy, adverse event reporting, and statutory informed consent.
Willowbrook Hepatitis Study 1956–1970s Children with intellectual disabilities Deliberate viral infection; coercive consent leveraged through institution admission access 45 CFR 46 Subpart D: Special protections and strict risk categories for pediatric populations in clinical trials.
Jewish Chronic Disease Hospital 1963 Elderly, debilitated cancer/stroke patients Subcutaneous injection of live cancer cells without informing patients of the neoplastic nature Institutional Review Board (IRB) Mandate: Independent prospective ethical review and written consent disclosure rules.
Tuskegee Syphilis Study 1932–1972 Economically disadvantaged African American men Withholding standard curative therapy (penicillin); deception; exploitation of racial/economic vulnerability National Research Act (1974) & Belmont Report (1979): Codification of Respect for Persons, Beneficence, and Justice.
3. The Nuremberg Code (1947): The 10 Inviolable Principles
The Nuremberg Code represented the world's first comprehensive international standard for the ethical conduct of research involving human participants. It shifted the ethical center of gravity from the unchecked authority of the physician-investigator to the autonomous rights of the individual participant.
The 10 Directives of the Nuremberg Code:
Voluntary Informed Consent is Absolutely Essential: The participant must possess legal capacity to give consent, exercise free power of choice without the intervention of force, fraud, deceit, duress, or coercion, and have sufficient knowledge and comprehension of the elements of the study.
Fruitful Results for the Good of Society: The experiment must be designed to yield fruitful results for the good of society, unprocurable by other methods or means of study, and not random or unnecessary in nature.
Prior Animal Experimentation & Scientific Rationale: The experiment must be based on prior animal experimentation and a thorough knowledge of the natural history of the disease or problem under study.
Avoidance of Unnecessary Physical and Mental Suffering: The experiment must be conducted to avoid all unnecessary physical and mental suffering and injury.
Prohibition of Lethal or Disabling Experiments: No experiment should be conducted where there is an a priori reason to believe that death or disabling injury will occur, except perhaps in those experiments where the experimental physicians also serve as subjects.
Proportionality of Risk to Humanitarian Importance: The degree of risk to be taken must never exceed that determined by the humanitarian importance of the problem to be solved by the experiment.
Adequate Preparations and Protective Facilities: Proper preparations must be made and adequate facilities provided to protect the experimental subject against even remote possibilities of injury, disability, or death.
Execution Only by Scientifically Qualified Persons: The experiment must be conducted only by scientifically qualified persons who possess the highest degree of skill and care throughout all stages.
Subject's Unrestricted Liberty to Terminate Participation: The human subject must be at liberty to bring the experiment to an end at any time if they have reached a physical or mental state where continuation seems impossible.
Investigator's Duty to Terminate Experiment: The scientist in charge must be prepared to terminate the experiment at any stage if they have probable cause to believe that continuation is likely to result in injury, disability, or death to the subject.
Exam Note: While the Nuremberg Code established foundational ethical principles, it had practical limitations: it was formulated in the context of criminal war crimes proceedings, did not provide practical operational guidance for clinical medicine or pediatric/proxy consent, and lacked mechanisms for institutional oversight (such as IRBs).
4. The Declaration of Helsinki (WMA 1964 to Present)
Recognizing the limitations of the Nuremberg Code for practicing physicians conducting clinical research, the World Medical Association (WMA) adopted the Declaration of Helsinki in 1964 in Helsinki, Finland. It has been revised and amended numerous times (most notably in Tokyo 1975, Edinburgh 2000, Seoul 2008 and Fortaleza 2013). The current version was adopted at the 75th WMA General Assembly in Helsinki in October 2024 and is titled Ethical Principles for Medical Research Involving Human Participants — the 2024 revision replaced "subjects" with "participants" throughout, strengthened provisions on scientific integrity, inclusivity and data privacy, and renumbered the paragraphs. Quote the 2024 numbering: ¶7 (the purposes of research can never take precedence over the rights and interests of individual research participants), ¶22 (protocol must state funding sources and potential conflicts of interest), ¶26 (the same must be disclosed during consent), ¶34 (post-trial provisions), ¶35 (registration before recruitment of the first participant) and ¶36 (duty to publish, including negative and inconclusive results). ┌───────────────────────────────────────────────────────────────────────────┐
- │ PILLARS OF THE DECLARATION OF HELSINKI (WMA) │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 1. PRIMACY OF THE INDIVIDUAL │
- │ • Well-being of the subject must take precedence over science/society │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 2. INDEPENDENT ETHICAL REVIEW │
- │ • Mandatory protocol review and approval by an independent committee │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 3. STRICT INFORMED CONSENT STANDARDS │
- │ • Written, voluntary, informed; explicit rules for proxy/LAR consent │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 4. PLACEBO & STANDARD-OF-CARE RESTRICTIONS │
- │ • New interventions tested against BEST PROVEN intervention │
- │ • Placebo permitted only when no proven therapy exists OR for │
- │ compelling scientific reasons with NO risk of serious harm │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 5. POST-TRIAL ACCESS & BENEFIT SHARING │
- │ • Sponsors must provide post-trial access to proven beneficial drugs │
- ├───────────────────────────────────────────────────────────────────────────┤
- │ 6. PUBLICATION & TRANSPARENCY INTEGRITY │
- │ • Negative, inconclusive, and positive results must be published │
- └───────────────────────────────────────────────────────────────────────────┘
Core Tenets of the Declaration of Helsinki:
Primacy of the Human Subject: Paragraph 7 of the 2024 revision declares that these purposes "can never take precedence over the rights and interests of individual research participants."
The Physician's Ethical Duty: Binds the physician to the Geneva declaration: "The health of my patient will be my first consideration."
Independent Ethics Committee (IEC) Mandate: Research protocols must be submitted for consideration, comment, guidance, and approval to the concerned research ethics committee before the study begins.
Scientific Validity & Environmental Responsibility: Research must conform to generally accepted scientific principles, be based on thorough knowledge of scientific literature, and respect environmental welfare.
The Placebo Controversy (Paragraph 33): The Declaration takes a restrictive stance on placebo controls. The benefits, risks, burdens, and effectiveness of a new intervention must be tested against those of the best proven intervention(s) . A placebo or no treatment is acceptable only when:
No proven intervention exists; or
For compelling and scientifically sound methodological reasons, the use of any intervention less effective than the best proven one, the use of placebo, or no intervention is necessary to determine the efficacy or safety of an intervention, and the patients will not be subject to additional risks of serious or irreversible harm .
Post-Trial Provisions (Paragraph 34): In advance of a clinical trial, sponsors, researchers, and host country governments must make provisions for post-trial access for all participants who still need an intervention identified as beneficial in the trial.
Publication Ethics & Trial Registration (Paragraphs 35–36): Every clinical trial must be registered in a publicly accessible database (e.g., ClinicalTrials.gov) before recruitment. Researchers have an ethical obligation to publish both positive and negative/inconclusive results, disclose conflicts of interest, and avoid duplicate or distorted publications.
5. The Belmont Report (1979) and National Research Act of 1974
Following the public exposure of the Tuskegee Syphilis Study, the United States Congress enacted the National Research Act of 1974 , creating the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research .
The Commission convened at the Smithsonian Institution's Belmont Conference Center in 1976 and issued its landmark summary in September 1979: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research .
The Foundational Triad of the Belmont Report:
Respect for Persons: Acknowledges personal autonomy and mandates the protection of individuals with diminished autonomy. Operationalized through the Informed Consent process (information, comprehension, voluntariness).
Beneficence: Obligates researchers to "do no harm" (non-maleficence) and to maximize possible benefits while minimizing possible harms. Operationalized through the systematic Assessment of Risks and Benefits .
Justice: Mandates fairness in the distribution of research burdens and benefits, requiring that vulnerable populations not be exploited for the benefit of more privileged classes. Operationalized through the equitable Selection of Subjects .
Codification into Federal Regulations (The Common Rule & FDA CFRs)
The principles of the Belmont Report served as the direct philosophical blueprint for U.S. federal regulations:
45 CFR 46 (Department of Health and Human Services - Common Rule): Governs federally funded research, establishing subparts for vulnerable populations (Subpart B: Pregnant Women/Fetuses; Subpart C: Prisoners; Subpart D: Children).
21 CFR 50 (FDA Informed Consent): Establishes mandatory elements and documentation of informed consent for FDA-regulated products.
21 CFR 56 (FDA Institutional Review Boards): Establishes the composition, operation, review criteria, and records of IRBs.
6. Comparative Architecture of Global Ethical Frameworks
Feature Nuremberg Code (1947) Declaration of Helsinki (1964/2024) Belmont Report (1979) ICH E6(R3) (1996/2025)
Originating Body U.S. Military Tribunal (Judicial Ruling) World Medical Association (WMA) National Commission / US Congress International Council for Harmonisation (ICH)
Legal Status Foundational Human Rights Landmark International Medical Ethics Code Philosophical Basis of US Law (45 CFR 46) International Harmonized Regulatory Standard
Core Focus Permissible non-therapeutic human experiments Medical research by physicians / clinical trials Philosophical principles guiding human research Operational, quality, and regulatory execution of clinical trials
IRB / Ethics Committee Not mentioned Explicit requirement (IEC) Explicit requirement (IRB review) Comprehensive IRB/IEC composition & responsibilities
Vulnerable Populations Assumes adult capacity for consent Comprehensive protections & proxy consent rules Explicit framework for diminished autonomy & justice Detailed operational guidelines for vulnerable groups
Placebo Control Stance Not addressed Must justify against best proven therapy Implicit in risk/benefit assessment Governed by ICH E10 (Choice of Control Group)